APO RESEARCH · REPORT
Biopharmaceuticals
A biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial.
Product & engineering
Understand the product.
A biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial.
Selected research
Industry Research
Biopharmaceuticals Industry Research Report 2026
Market perspective
A biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial.
The global Biopharmaceuticals market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Biopharmaceuticals market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Biopharmaceuticals market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Biopharmaceuticals market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Biopharmaceuticals include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Read the full market overview
Report Scope
This report quantifies the global Biopharmaceuticals market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Biopharmaceuticals.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biopharmaceuticals Market by Company
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Sun
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
SANDOZ (NOVARTIS)
Teva Pharmaceutical
Hospira （Pfizer）
MYLAN
Sun pharma
Biopharmaceuticals Segment by Type
Monoclonal Antibodies
Interferon
Colony-Stimulating Factor
Erythropoietin
Insulin
Vaccines
Growth Hormones
Others
Biopharmaceuticals Segment by Application
Tumor
Diabetes
Cardiovascular
Hemophilia
Others
Biopharmaceuticals Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biopharmaceuticals companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monoclonal Antibodies
- Interferon
- Colony-Stimulating Factor
- Erythropoietin
- Insulin
- Vaccines
- Growth Hormones
- Others
Applications
- Tumor
- Diabetes
- Cardiovascular
- Hemophilia
- Others
Companies covered
- Roche
- Amgen
- AbbVie
- Sanofi-Aventis
- Johnson & Johnson
- Pfizer
- Novo Nordisk
- Eli Lilly
- Novartis
- Merck
- Sun
- 3sbio
- Changchun High Tech
- CP Guojian
- Biotech
- Gelgen
- Innovent
- Dong Bao
- Ganlee
- United Laboratories
- SANDOZ (NOVARTIS)
- Teva Pharmaceutical
- Hospira （Pfizer）
- MYLAN
- Sun pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Biopharmaceuticals by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Monoclonal Antibodies
- 2.2.3 Interferon
- 2.2.4 Colony-Stimulating Factor
- 2.2.5 Erythropoietin
- 2.2.6 Insulin
- 2.2.7 Vaccines
- 2.2.8 Growth Hormones
- 2.2.9 Others
- 2.3 Biopharmaceuticals by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Tumor
- 2.3.3 Diabetes
- 2.3.4 Cardiovascular
- 2.3.5 Hemophilia
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Biopharmaceuticals Breakdown Data by Type
- 3.1 Global Biopharmaceuticals Historic Market Size by Type (2021-2026)
- 3.2 Global Biopharmaceuticals Forecasted Market Size by Type (2027-2032)
4 Biopharmaceuticals Breakdown Data by Application
- 4.1 Global Biopharmaceuticals Historic Market Size by Application (2021-2026)
- 4.2 Global Biopharmaceuticals Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Biopharmaceuticals Market Perspective (2021-2032)
- 5.2 Global Biopharmaceuticals Growth Trends by Region
- 5.2.1 Global Biopharmaceuticals Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Biopharmaceuticals Historic Market Size by Region (2021-2026)
- 5.2.3 Biopharmaceuticals Forecasted Market Size by Region (2027-2032)
- 5.3 Biopharmaceuticals Market Dynamics
- 5.3.1 Biopharmaceuticals Industry Trends
- 5.3.2 Biopharmaceuticals Market Drivers
- 5.3.3 Biopharmaceuticals Market Challenges
- 5.3.4 Biopharmaceuticals Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Biopharmaceuticals Players by Revenue
- 6.1.1 Global Top Biopharmaceuticals Players by Revenue (2021-2026)
- 6.1.2 Global Biopharmaceuticals Revenue Market Share by Players (2021-2026)
- 6.2 Global Biopharmaceuticals Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Biopharmaceuticals Head Office and Area Served
- 6.4 Global Biopharmaceuticals Players, Product Type & Application
- 6.5 Global Biopharmaceuticals Manufacturers Established Date
- 6.6 Global Biopharmaceuticals Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Biopharmaceuticals Market Size (2021-2032)
- 7.2 North America Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Biopharmaceuticals Market Size by Country (2021-2026)
- 7.4 North America Biopharmaceuticals Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Biopharmaceuticals Market Size (2021-2032)
- 8.2 Europe Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Biopharmaceuticals Market Size by Country (2021-2026)
- 8.4 Europe Biopharmaceuticals Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Biopharmaceuticals Market Size (2021-2032)
- 9.2 Asia-Pacific Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Biopharmaceuticals Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Biopharmaceuticals Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Biopharmaceuticals Market Size (2021-2032)
- 10.2 South America Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Biopharmaceuticals Market Size by Country (2021-2026)
- 10.4 South America Biopharmaceuticals Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Biopharmaceuticals Market Size (2021-2032)
- 11.2 Middle East & Africa Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Biopharmaceuticals Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Biopharmaceuticals Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Roche
- 12.1.1 Roche Company Information
- 12.1.2 Roche Business Overview
- 12.1.3 Roche Revenue in Biopharmaceuticals Business (2021-2026)
- 12.1.4 Roche Biopharmaceuticals Product Portfolio
- 12.1.5 Roche Recent Developments
- 12.2 Amgen
- 12.2.1 Amgen Company Information
- 12.2.2 Amgen Business Overview
- 12.2.3 Amgen Revenue in Biopharmaceuticals Business (2021-2026)
- 12.2.4 Amgen Biopharmaceuticals Product Portfolio
- 12.2.5 Amgen Recent Developments
- 12.3 AbbVie
- 12.3.1 AbbVie Company Information
- 12.3.2 AbbVie Business Overview
- 12.3.3 AbbVie Revenue in Biopharmaceuticals Business (2021-2026)
- 12.3.4 AbbVie Biopharmaceuticals Product Portfolio
- 12.3.5 AbbVie Recent Developments
- 12.4 Sanofi-Aventis
- 12.4.1 Sanofi-Aventis Company Information
- 12.4.2 Sanofi-Aventis Business Overview
- 12.4.3 Sanofi-Aventis Revenue in Biopharmaceuticals Business (2021-2026)
- 12.4.4 Sanofi-Aventis Biopharmaceuticals Product Portfolio
- 12.4.5 Sanofi-Aventis Recent Developments
- 12.5 Johnson & Johnson
- 12.5.1 Johnson & Johnson Company Information
- 12.5.2 Johnson & Johnson Business Overview
- 12.5.3 Johnson & Johnson Revenue in Biopharmaceuticals Business (2021-2026)
- 12.5.4 Johnson & Johnson Biopharmaceuticals Product Portfolio
- 12.5.5 Johnson & Johnson Recent Developments
- 12.6 Pfizer
- 12.6.1 Pfizer Company Information
- 12.6.2 Pfizer Business Overview
- 12.6.3 Pfizer Revenue in Biopharmaceuticals Business (2021-2026)
- 12.6.4 Pfizer Biopharmaceuticals Product Portfolio
- 12.6.5 Pfizer Recent Developments
- 12.7 Novo Nordisk
- 12.7.1 Novo Nordisk Company Information
- 12.7.2 Novo Nordisk Business Overview
- 12.7.3 Novo Nordisk Revenue in Biopharmaceuticals Business (2021-2026)
- 12.7.4 Novo Nordisk Biopharmaceuticals Product Portfolio
- 12.7.5 Novo Nordisk Recent Developments
- 12.8 Eli Lilly
- 12.8.1 Eli Lilly Company Information
- 12.8.2 Eli Lilly Business Overview
- 12.8.3 Eli Lilly Revenue in Biopharmaceuticals Business (2021-2026)
- 12.8.4 Eli Lilly Biopharmaceuticals Product Portfolio
- 12.8.5 Eli Lilly Recent Developments
- 12.9 Novartis
- 12.9.1 Novartis Company Information
- 12.9.2 Novartis Business Overview
- 12.9.3 Novartis Revenue in Biopharmaceuticals Business (2021-2026)
- 12.9.4 Novartis Biopharmaceuticals Product Portfolio
- 12.9.5 Novartis Recent Developments
- 12.10 Merck
- 12.10.1 Merck Company Information
- 12.10.2 Merck Business Overview
- 12.10.3 Merck Revenue in Biopharmaceuticals Business (2021-2026)
- 12.10.4 Merck Biopharmaceuticals Product Portfolio
- 12.10.5 Merck Recent Developments
- 12.11 Sun
- 12.11.1 Sun Company Information
- 12.11.2 Sun Business Overview
- 12.11.3 Sun Revenue in Biopharmaceuticals Business (2021-2026)
- 12.11.4 Sun Biopharmaceuticals Product Portfolio
- 12.11.5 Sun Recent Developments
- 12.12 3sbio
- 12.12.1 3sbio Company Information
- 12.12.2 3sbio Business Overview
- 12.12.3 3sbio Revenue in Biopharmaceuticals Business (2021-2026)
- 12.12.4 3sbio Biopharmaceuticals Product Portfolio
- 12.12.5 3sbio Recent Developments
- 12.13 Changchun High Tech
- 12.13.1 Changchun High Tech Company Information
- 12.13.2 Changchun High Tech Business Overview
- 12.13.3 Changchun High Tech Revenue in Biopharmaceuticals Business (2021-2026)
- 12.13.4 Changchun High Tech Biopharmaceuticals Product Portfolio
- 12.13.5 Changchun High Tech Recent Developments
- 12.14 CP Guojian
- 12.14.1 CP Guojian Company Information
- 12.14.2 CP Guojian Business Overview
- 12.14.3 CP Guojian Revenue in Biopharmaceuticals Business (2021-2026)
- 12.14.4 CP Guojian Biopharmaceuticals Product Portfolio
- 12.14.5 CP Guojian Recent Developments
- 12.15 Biotech
- 12.15.1 Biotech Company Information
- 12.15.2 Biotech Business Overview
- 12.15.3 Biotech Revenue in Biopharmaceuticals Business (2021-2026)
- 12.15.4 Biotech Biopharmaceuticals Product Portfolio
- 12.15.5 Biotech Recent Developments
- 12.16 Gelgen
- 12.16.1 Gelgen Company Information
- 12.16.2 Gelgen Business Overview
- 12.16.3 Gelgen Revenue in Biopharmaceuticals Business (2021-2026)
- 12.16.4 Gelgen Biopharmaceuticals Product Portfolio
- 12.16.5 Gelgen Recent Developments
- 12.17 Innovent
- 12.17.1 Innovent Company Information
- 12.17.2 Innovent Business Overview
- 12.17.3 Innovent Revenue in Biopharmaceuticals Business (2021-2026)
- 12.17.4 Innovent Biopharmaceuticals Product Portfolio
- 12.17.5 Innovent Recent Developments
- 12.18 Dong Bao
- 12.18.1 Dong Bao Company Information
- 12.18.2 Dong Bao Business Overview
- 12.18.3 Dong Bao Revenue in Biopharmaceuticals Business (2021-2026)
- 12.18.4 Dong Bao Biopharmaceuticals Product Portfolio
- 12.18.5 Dong Bao Recent Developments
- 12.19 Ganlee
- 12.19.1 Ganlee Company Information
- 12.19.2 Ganlee Business Overview
- 12.19.3 Ganlee Revenue in Biopharmaceuticals Business (2021-2026)
- 12.19.4 Ganlee Biopharmaceuticals Product Portfolio
- 12.19.5 Ganlee Recent Developments
- 12.20 United Laboratories
- 12.20.1 United Laboratories Company Information
- 12.20.2 United Laboratories Business Overview
- 12.20.3 United Laboratories Revenue in Biopharmaceuticals Business (2021-2026)
- 12.20.4 United Laboratories Biopharmaceuticals Product Portfolio
- 12.20.5 United Laboratories Recent Developments
- 12.21 SANDOZ (NOVARTIS)
- 12.21.1 SANDOZ (NOVARTIS) Company Information
- 12.21.2 SANDOZ (NOVARTIS) Business Overview
- 12.21.3 SANDOZ (NOVARTIS) Revenue in Biopharmaceuticals Business (2021-2026)
- 12.21.4 SANDOZ (NOVARTIS) Biopharmaceuticals Product Portfolio
- 12.21.5 SANDOZ (NOVARTIS) Recent Developments
- 12.22 Teva Pharmaceutical
- 12.22.1 Teva Pharmaceutical Company Information
- 12.22.2 Teva Pharmaceutical Business Overview
- 12.22.3 Teva Pharmaceutical Revenue in Biopharmaceuticals Business (2021-2026)
- 12.22.4 Teva Pharmaceutical Biopharmaceuticals Product Portfolio
- 12.22.5 Teva Pharmaceutical Recent Developments
- 12.23 Hospira （Pfizer）
- 12.23.1 Hospira （Pfizer） Company Information
- 12.23.2 Hospira （Pfizer） Business Overview
- 12.23.3 Hospira （Pfizer） Revenue in Biopharmaceuticals Business (2021-2026)
- 12.23.4 Hospira （Pfizer） Biopharmaceuticals Product Portfolio
- 12.23.5 Hospira （Pfizer） Recent Developments
- 12.24 MYLAN
- 12.24.1 MYLAN Company Information
- 12.24.2 MYLAN Business Overview
- 12.24.3 MYLAN Revenue in Biopharmaceuticals Business (2021-2026)
- 12.24.4 MYLAN Biopharmaceuticals Product Portfolio
- 12.24.5 MYLAN Recent Developments
- 12.25 Sun pharma
- 12.25.1 Sun pharma Company Information
- 12.25.2 Sun pharma Business Overview
- 12.25.3 Sun pharma Revenue in Biopharmaceuticals Business (2021-2026)
- 12.25.4 Sun pharma Biopharmaceuticals Product Portfolio
- 12.25.5 Sun pharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst